StockData
MBX Biosciences, Inc. logo

MBX Biosciences, Inc. (MBX) stock

MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$53.42+0.32 (+0.60%)

Close on Nov 18, 2026Market cap $2.57BP/E –Yield –

MBX Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

MBX Biosciences's free cash flow for the twelve months ending Sep 30, 2026 was -$99.33M. For fiscal 2025 it was -$81.88M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$81.88M–
FY2024Dec 31, 2024-$55.56M–
FY2023Dec 31, 2023-$32.11M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$36.07M–
Q2 FY2026Jun 30, 2026-$23.52M–
Q1 FY2026Mar 31, 2026-$20.65M–
Q4 FY2025Dec 31, 2025-$19.09M–
Q3 FY2025Sep 30, 2025-$21.94M–
Q2 FY2025Jun 30, 2025-$18.14M–
Q1 FY2025Mar 31, 2025-$22.71M–
Q4 FY2024Dec 31, 2024-$16.13M–
Q3 FY2024Sep 30, 2024-$14.72M–
Q2 FY2024Jun 30, 2024-$13.72M–
Q1 FY2024Mar 31, 2024-$10.98M–
Q4 FY2023Dec 31, 2023-$11.20M–

More MBX Biosciences figures

See a number that looks wrong?